US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Telix Pharmaceuticals Ltd. (Uplisting)

12.58

+0.75006.34%

Volume:179.36K

Turnover:2.26M

Market Cap:4.26B

PE:131.89

High:12.72

Open:12.45

Low:12.38

Close:11.83

52wk High:13.11

52wk Low:6.28

Shares:339.00M

Float Shares:272.00M

Volume Ratio:1.31

T/O Rate:0.07%

Dividend:- -

Dividend Rate:- -

EPS(TTM):0.0954

EPS(LYR):-0.0211

ROE:7.36%

ROA:2.71%

PB:8.74

PE(LYR):-596.21

Loading ...

Overview Company News Filings

Jarden Sticks to Their Buy Rating for Telix Pharmaceuticals (TLPPF)

Telix Adds High-Profile Directors to Bolster Global Biopharma Push

Press Release: Telix Strengthens Board with Additional Director Appointments

Telix appoints Maria Rivas, Bill Jellison as non-executive directors

Jarden Adjusts Telix Pharmaceuticals's Price Target to AU$21.80 from AU$21, Keeps at Buy

MT Newswires Live

Morgan Stanley Sticks to Its Buy Rating for Telix Pharmaceuticals (TLPPF)

Telix Pharmaceuticals (TLPPF) Gets a Buy from Canaccord Genuity

Telix Pharmaceuticals US PSMA PET Sales Gain Traction, Seen to Grow Market Share, Says Jefferies

MT Newswires Live

Why Is Telix Pharma Stock Soaring Tuesday?

Benzinga Earnings

Exchange-Traded Funds, Equity Futures Lower Pre-Bell Tuesday Ahead of Trump's Hormuz Reopening Deadline

MT Newswires Live

Telix Pharmaceuticals Price Target Maintained With a $20.00/Share by HC Wainwright & Co.

Telix Pharmaceuticals Q1 Revenue Rises 24%; Shares Gain 6%

MT Newswires Live

Analysts Have Conflicting Sentiments on These Healthcare Companies: CSL (OtherCMXHF) and Telix Pharmaceuticals (OtherTLPPF)

Will Telix (ASX:TLX) Board Refresh Subtly Recast Its Governance And Growth Balancing Act?

Simply Wall St.

Citi Group Entities Exit Substantial Holder Status in Telix Pharmaceuticals

Telix Appoints David Gill as Non-Executive Director

Telix Pharmaceuticals (ASX:TLX) Is Up 7.1% After Resubmitting TLX101-Px NDA With FDA Fast Track Designation - Has The Bull Case Changed?

Simply Wall St.

ASX Growth Companies With Insider Ownership Up To 38%

Simply Wall St.

A Look At Telix Pharmaceuticals (ASX:TLX) Valuation After Key TLX101-Px And TLX591-Tx Trial Updates

Simply Wall St.

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"Tiger Brokers,U.S. stock trading,Hong Kong stock trading,trading U.S. stocks,stock information,stock prices,U.S. stock quotes,U.S. stock trading,Hong Kong stock trading,IPO trading,buying U.S. stocks,global investment","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.thetigerbrokers.com/stock/TLX/news?page=10"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental","symbol":"TLX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"TLX\",,,,,undefined,":{"symbol":"TLX","market":"US","secType":"STK","nameCN":"Telix Pharmaceuticals Ltd. (Uplisting)","latestPrice":12.58,"timestamp":1789656939835,"preClose":11.83,"halted":0,"volume":179364,"delay":0,"changeRate":0.06339814032121724,"floatShares":272000000,"shares":339000000,"eps":0.095386,"marketStatus":"Trading","change":0.75,"latestTime":"09-17 10:55:42 EDT","open":12.45,"high":12.7196,"low":12.375,"amount":2256345.669528,"amplitude":0.029129,"askPrice":12.6,"askSize":282,"bidPrice":12.58,"bidSize":272,"shortable":3,"etf":0,"ttmEps":0.095386,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1789675200000},"marketStatusCode":2,"adr":0,"adrRate":1,"listingDate":1718337600000,"exchange":"NASDAQ","adjPreClose":11.83,"preHourTrading":{"tag":"盘前","latestPrice":12.48,"preClose":11.83,"latestTime":"09:29 EDT","volume":5572,"amount":68507.249664,"timestamp":1789651763576,"change":0.65,"changeRate":0.054945,"amplitude":0.032122},"postHourTrading":{"tag":"盘后","latestPrice":11.98,"preClose":11.83,"latestTime":"19:30 EDT","volume":294,"amount":3512.04,"timestamp":1789601404658,"change":0.15,"changeRate":0.01268,"amplitude":0.01268},"volumeRatio":1.309913},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"TLX\",,,,,undefined,":{"symbol":"TLX","floatShares":272000000,"roa":"2.71%","roe":"7.36%","lyrEps":-0.0211,"volumeRatio":1.309913,"shares":339000000,"dividePrice":0,"high":12.7196,"amplitude":0.029129,"preClose":11.83,"low":12.375,"week52Low":6.28,"pbRate":"8.74","psRate":"4.79","week52High":13.1098,"institutionHeld":0,"latestPrice":12.58,"committee":-0.018051,"eps":0.095386,"divideRate":0,"volume":179364,"delay":0,"ttmEps":0.095386,"open":12.45,"prevYearClose":7.49,"prevWeekClose":11.29,"prevMonthClose":11.09,"prevQuarterClose":11.53,"fiveDayClose":11.9,"twentyDayClose":12.12,"sixtyDayClose":10.21},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/TLX\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-02-19","symbol":"TLX","fiscalQuarterEnding":"2025/12","expectedEps":0.04,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1771477200000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2025-08-20","symbol":"TLX","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1755662400000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2025-02-20","symbol":"TLX","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1740027600000,"reportTimeType":"pre","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"TLX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"TLX\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.6,"buy":0.4,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.6,"analysts":5,"updateTime":1758254400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/TLX\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"TLX","date":"2026-09-16","current":131.885182,"percent":0.323144,"low":-584.49693,"twenty":-440.382961,"median":170.43171,"eighty":242.673364,"high":383.853933,"avg":25.517257,"sd":309.341749,"marketCap":4088559942.23},"quantilePoints":[{"date":"2024-11-15","current":155.824924,"twenty":155.852142,"median":155.89297,"eighty":156.178762,"marketCap":4970652360.72},{"date":"2024-11-22","current":153.647458,"twenty":154.191824,"median":155.858947,"eighty":156.314854,"marketCap":4920980791.17},{"date":"2024-11-29","current":168.345354,"twenty":154.8995,"median":156.063085,"eighty":158.49232,"marketCap":5381208976.41},{"date":"2024-12-06","current":169.502133,"twenty":155.171684,"median":156.641474,"eighty":168.045953,"marketCap":5368295184.8},{"date":"2024-12-13","current":166.916392,"twenty":155.838533,"median":162.3233,"eighty":168.045953,"marketCap":5240175366.69},{"date":"2024-12-20","current":168.345354,"twenty":155.961016,"median":166.508117,"eighty":168.916939,"marketCap":5183140063.85},{"date":"2024-12-27","current":169.774316,"twenty":156.233199,"median":167.052484,"eighty":169.706271,"marketCap":5196235069.7},{"date":"2025-01-03","current":162.241165,"twenty":156.342072,"median":167.052484,"eighty":169.542961,"marketCap":4949346723.31},{"date":"2025-01-10","current":163.261978,"twenty":156.5326,"median":167.392713,"eighty":169.228803,"marketCap":4970930045.19},{"date":"2025-01-17","current":180.956065,"twenty":158.029608,"median":167.50507,"eighty":169.864326,"marketCap":5535715919.89},{"date":"2025-01-24","current":187.353158,"twenty":159.608271,"median":167.889662,"eighty":170.577257,"marketCap":5785750657.37},{"date":"2025-01-31","current":199.670965,"twenty":161.249345,"median":168.229933,"eighty":175.407845,"marketCap":6122321793.53},{"date":"2025-02-07","current":198.349538,"twenty":162.241165,"median":168.549491,"eighty":182.861582,"marketCap":6131109878.71},{"date":"2025-02-14","current":185.473256,"twenty":162.64949,"median":169.046583,"eighty":187.353158,"marketCap":5747906307.1},{"date":"2025-02-21","current":203.261161,"twenty":163.302811,"median":169.706271,"eighty":187.353158,"marketCap":6486347833.54},{"date":"2025-02-28","current":187.883767,"twenty":163.584606,"median":170.12499,"eighty":192.087093,"marketCap":5864055113.17},{"date":"2025-03-07","current":182.602424,"twenty":164.112905,"median":170.795004,"eighty":190.960114,"marketCap":5800401146.04},{"date":"2025-03-14","current":179.829719,"twenty":164.766144,"median":174.911776,"eighty":189.692293,"marketCap":5647282174.13},{"date":"2025-03-21","current":184.714961,"twenty":166.589772,"median":175.670662,"eighty":188.147066,"marketCap":5803981960.09},{"date":"2025-03-28","current":187.327482,"twenty":166.94361,"median":178.971501,"eighty":190.960114,"marketCap":5900183330.18},{"date":"2025-04-04","current":159.860903,"twenty":166.94361,"median":178.262158,"eighty":189.692293,"marketCap":5073492527.81},{"date":"2025-04-11","current":177.179731,"twenty":166.589772,"median":177.679515,"eighty":188.147066,"marketCap":5496976372.28},{"date":"2025-04-17","current":173.797147,"twenty":166.916392,"median":177.619467,"eighty":187.883767,"marketCap":5535140863.85},{"date":"2025-04-25","current":193.309359,"twenty":167.052484,"median":178.059203,"eighty":190.062144,"marketCap":6172717887.8},{"date":"2025-05-02","current":198.453445,"twenty":167.392713,"median":178.295984,"eighty":190.062144,"marketCap":6327668326.52},{"date":"2025-05-09","current":181.396737,"twenty":167.481337,"median":179.235568,"eighty":190.062144,"marketCap":5809793224.05},{"date":"2025-05-16","current":176.029393,"twenty":167.481337,"median":178.295984,"eighty":189.78972,"marketCap":5619140101.04},{"date":"2025-05-23","current":172.647682,"twenty":167.528804,"median":178.059203,"eighty":189.451294,"marketCap":5528513460.13},{"date":"2025-05-30","current":176.779306,"twenty":167.780801,"median":177.456621,"eighty":188.460572,"marketCap":5687082652.57},{"date":"2025-06-06","current":173.121803,"twenty":167.88049,"median":177.318176,"eighty":187.949592,"marketCap":5638091901.1},{"date":"2025-06-13","current":167.838743,"twenty":167.88049,"median":176.508379,"eighty":187.45928,"marketCap":5463186103.94},{"date":"2025-06-20","current":168.923551,"twenty":167.889662,"median":176.029393,"eighty":187.353158,"marketCap":5442074695.06},{"date":"2025-06-27","current":165.669807,"twenty":167.592888,"median":175.625224,"eighty":187.337752,"marketCap":5412704421.76},{"date":"2025-07-03","current":162.348276,"twenty":167.428163,"median":175.082406,"eighty":187.024133,"marketCap":5325445922.59},{"date":"2025-07-11","current":163.297285,"twenty":166.671427,"median":174.480785,"eighty":186.439488,"marketCap":5350247552.51},{"date":"2025-07-18","current":171.228286,"twenty":165.90028,"median":173.909122,"eighty":186.045921,"marketCap":5541358073.91},{"date":"2025-07-25","current":144.045965,"twenty":165.670181,"median":173.731386,"eighty":185.637634,"marketCap":4750367012.62},{"date":"2025-08-01","current":136.589468,"twenty":164.955304,"median":173.25664,"eighty":185.381192,"marketCap":4384547406.6},{"date":"2025-08-08","current":119.575098,"twenty":163.364827,"median":173.121803,"eighty":185.031841,"marketCap":3879545892.37},{"date":"2025-08-15","current":118.626089,"twenty":162.985468,"median":172.816584,"eighty":184.520886,"marketCap":3844757658.1},{"date":"2025-08-22","current":367.342977,"twenty":162.565192,"median":172.783145,"eighty":185.031841,"marketCap":3983594342.69},{"date":"2025-08-29","current":297.28853,"twenty":162.917681,"median":173.086118,"eighty":186.439488,"marketCap":3223899680.91},{"date":"2025-09-05","current":280.194275,"twenty":162.97191,"median":173.155042,"eighty":187.353158,"marketCap":3038523660.62},{"date":"2025-09-12","current":284.24913,"twenty":163.053254,"median":173.392729,"eighty":189.722035,"marketCap":3082495919.22},{"date":"2025-09-19","current":299.993591,"twenty":163.181765,"median":173.840405,"eighty":192.411646,"marketCap":3253234303.96},{"date":"2025-09-26","current":303.368871,"twenty":163.269039,"median":174.34097,"eighty":195.332201,"marketCap":3289837005.56},{"date":"2025-10-03","current":316.222238,"twenty":163.331056,"median":174.844246,"eighty":197.182743,"marketCap":3429223360.77},{"date":"2025-10-10","current":308.943311,"twenty":163.584606,"median":175.579785,"eighty":198.432664,"marketCap":3350288154.24},{"date":"2025-10-17","current":337.724829,"twenty":164.112905,"median":175.99796,"eighty":200.117317,"marketCap":3662404902.51},{"date":"2025-10-24","current":335.676999,"twenty":164.422238,"median":176.508379,"eighty":204.373856,"marketCap":3640197520.67},{"date":"2025-10-31","current":328.898919,"twenty":164.871944,"median":177.318176,"eighty":280.077091,"marketCap":3566693671.28},{"date":"2025-11-07","current":302.845362,"twenty":165.230483,"median":178.059203,"eighty":285.744085,"marketCap":3284159889.46},{"date":"2025-11-14","current":289.051675,"twenty":165.371547,"median":178.295984,"eighty":290.299055,"marketCap":3134576370.19},{"date":"2025-11-21","current":278.19044,"twenty":165.561349,"median":179.014446,"eighty":289.541689,"marketCap":3016793389.39},{"date":"2025-11-28","current":310.533522,"twenty":165.669807,"median":179.412236,"eighty":291.060611,"marketCap":3367532955.32},{"date":"2025-12-05","current":306.208941,"twenty":165.670741,"median":180.00406,"eighty":294.691227,"marketCap":3320635708.33},{"date":"2025-12-12","current":286.055209,"twenty":165.873166,"median":180.584513,"eighty":295.905706,"marketCap":3102081667.78},{"date":"2025-12-19","current":244.707348,"twenty":165.940952,"median":181.091444,"eighty":294.691227,"marketCap":2653691145.03},{"date":"2025-12-26","current":248.848958,"twenty":166.394684,"median":181.60348,"eighty":294.390689,"marketCap":2698604201.29},{"date":"2026-01-02","current":236.757004,"twenty":166.574536,"median":182.507221,"eighty":293.840477,"marketCap":2567474872.89},{"date":"2026-01-09","current":234.880062,"twenty":166.797362,"median":182.734458,"eighty":292.111558,"marketCap":2547120662.92},{"date":"2026-01-16","current":240.619616,"twenty":166.998047,"median":183.212494,"eighty":291.104403,"marketCap":2609362374.53},{"date":"2026-01-23","current":233.793317,"twenty":167.188576,"median":183.578507,"eighty":290.823686,"marketCap":2535335622.99},{"date":"2026-01-30","current":230.611959,"twenty":167.428163,"median":183.988776,"eighty":290.419247,"marketCap":2500835870.83},{"date":"2026-02-06","current":214.320895,"twenty":167.500324,"median":184.979028,"eighty":290.056234,"marketCap":2324169939.4},{"date":"2026-02-13","current":194.105832,"twenty":167.571527,"median":185.74722,"eighty":289.461299,"marketCap":2104950801.53},{"date":"2026-02-20","current":-349.931165,"twenty":167.550165,"median":186.245055,"eighty":289.186438,"marketCap":2493259551.93},{"date":"2026-02-27","current":-337.576812,"twenty":166.94361,"median":185.358176,"eighty":288.884688,"marketCap":2405234781.68},{"date":"2026-03-06","current":-357.014534,"twenty":165.886723,"median":184.229774,"eighty":287.796958,"marketCap":2543728559.75},{"date":"2026-03-13","current":-380.87359,"twenty":165.371547,"median":183.661424,"eighty":286.105301,"marketCap":2713724328.68},{"date":"2026-03-20","current":-427.441295,"twenty":164.112905,"median":183.427298,"eighty":285.888656,"marketCap":3045519229.47},{"date":"2026-03-27","current":-448.04178,"twenty":163.181765,"median":182.800475,"eighty":285.212188,"marketCap":3192297684.03},{"date":"2026-04-02","current":-425.435204,"twenty":162.890567,"median":182.629922,"eighty":285.17117,"marketCap":3031225831.43},{"date":"2026-04-10","current":-492.382264,"twenty":161.467054,"median":181.810223,"eighty":284.24913,"marketCap":3508223631.57},{"date":"2026-04-17","current":-499.465833,"twenty":158.955031,"median":181.091444,"eighty":284.07528,"marketCap":3558694058.36},{"date":"2026-04-24","current":-507.89561,"twenty":156.233199,"median":180.584513,"eighty":282.031139,"marketCap":3618756217.23},{"date":"2026-05-01","current":-532.518745,"twenty":154.872282,"median":180.00406,"eighty":281.147736,"marketCap":3794196059.21},{"date":"2026-05-08","current":-508.824558,"twenty":144.045965,"median":179.412236,"eighty":280.966174,"marketCap":3625374971.37},{"date":"2026-05-15","current":-506.065728,"twenty":140.182144,"median":178.86094,"eighty":280.209239,"marketCap":3605718311.9},{"date":"2026-05-22","current":-452.537308,"twenty":125.947014,"median":178.262158,"eighty":280.194275,"marketCap":3224328322.29},{"date":"2026-05-29","current":-444.681415,"twenty":120.122064,"median":178.059203,"eighty":279.725537,"marketCap":3168355079.47},{"date":"2026-06-05","current":-452.683664,"twenty":115.968865,"median":177.318176,"eighty":279.589795,"marketCap":3225371110.32},{"date":"2026-06-12","current":-453.131496,"twenty":29.784924,"median":176.508379,"eighty":278.469383,"marketCap":3228561906.13},{"date":"2026-06-18","current":-479.232706,"twenty":-319.885885,"median":176.029393,"eighty":275.361846,"marketCap":3414533028.17},{"date":"2026-06-26","current":-505.22407,"twenty":-336.088027,"median":175.625224,"eighty":265.637187,"marketCap":3599721496.58},{"date":"2026-07-02","current":-567.292731,"twenty":-347.690038,"median":175.082406,"eighty":259.576863,"marketCap":4041960704.33},{"date":"2026-07-10","current":-538.02731,"twenty":-371.335373,"median":174.480785,"eighty":256.751103,"marketCap":3833444584.84},{"date":"2026-07-17","current":-497.824928,"twenty":-406.861587,"median":173.909122,"eighty":252.484997,"marketCap":3547002606.6},{"date":"2026-07-24","current":-487.362208,"twenty":-419.925535,"median":173.731386,"eighty":249.449835,"marketCap":3472455733.71},{"date":"2026-07-31","current":-475.018244,"twenty":-425.317007,"median":173.324997,"eighty":249.116107,"marketCap":3384504988.78},{"date":"2026-08-07","current":-543.110083,"twenty":-431.380818,"median":173.121803,"eighty":248.587668,"marketCap":3869659340.88},{"date":"2026-08-14","current":-563.285348,"twenty":-444.416873,"median":172.850024,"eighty":247.242146,"marketCap":4013408103.64},{"date":"2026-08-21","current":112.812357,"twenty":-445.662886,"median":172.57995,"eighty":245.774025,"marketCap":3778875522.96},{"date":"2026-08-28","current":114.191675,"twenty":-444.681415,"median":171.69944,"eighty":244.665977,"marketCap":3825078550.57},{"date":"2026-09-04","current":120.218119,"twenty":-444.416873,"median":171.125205,"eighty":244.246526,"marketCap":4026946335.18},{"date":"2026-09-11","current":113.993217,"twenty":-443.358706,"median":170.839525,"eighty":243.230652,"marketCap":3818430784.57},{"date":"2026-09-16","current":122.057496,"twenty":-440.382961,"median":170.43171,"eighty":242.673364,"marketCap":4088559942.23}],"updateTime":1789656942064},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"TLX\",pageSize:20,pageCount:10,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2626597646","title":"Jarden Sticks to Their Buy Rating for Telix Pharmaceuticals (TLPPF)","url":"https://stock-news.laohu8.com/highlight/detail?id=2626597646","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626597646?lang=en_us&edition=fundamental","pubTime":"2026-04-09 08:29","pubTimestamp":1775694540,"startTime":"0","endTime":"0","summary":"In a report released on April 7, Steven Wheen from Jarden maintained a Buy rating on Telix Pharmaceuticals, with a price target of A$21.80. The com...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/jarden-sticks-to-their-buy-rating-for-telix-pharmaceuticals-tlppf-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/jarden-sticks-to-their-buy-rating-for-telix-pharmaceuticals-tlppf-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TLPPF","TLX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626973660","title":"Telix Adds High-Profile Directors to Bolster Global Biopharma Push","url":"https://stock-news.laohu8.com/highlight/detail?id=2626973660","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626973660?lang=en_us&edition=fundamental","pubTime":"2026-04-09 07:07","pubTimestamp":1775689667,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals ( ($AU:TLX) ) just unveiled an announcement. Telix Pharmaceuticals has expanded its board with the appointment of two additio...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/telix-adds-high-profile-directors-to-bolster-global-biopharma-push?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/telix-adds-high-profile-directors-to-bolster-global-biopharma-push?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TLX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626978267","title":"Press Release: Telix Strengthens Board with Additional Director Appointments","url":"https://stock-news.laohu8.com/highlight/detail?id=2626978267","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626978267?lang=en_us&edition=fundamental","pubTime":"2026-04-09 06:44","pubTimestamp":1775688240,"startTime":"0","endTime":"0","summary":"MELBOURNE, Australia and INDIANAPOLIS, April 09, 2026  -- Telix Pharmaceuticals Limited  today announces two additional Non-Executive Director  appointments, effective May 11, 2026 , as part of Board expansion and succession planning:. -- Maria Rivas, MD is an experienced public company board director and S&P. 100 senior pharmaceutical executive with more than 25 years' experience. leadership. Dr. Rivas currently serves on the board of directors of The. Cooper Companies, Inc. , a medical technology company, and. years in healthcare developing and commercializing medical devices and. oncology, rare diseases and neurosciences, most recently as Chief Medical. Columbia University's Vagelos College of Physicians and Surgeons. She. completed residency training in Internal Medicine and a fellowship in. Solenis LLC, and Young Innovations, Inc., and until recently served as a. Corporation, overseeing international finance, SEC reporting, mergers and. Telix Interim Chair, Dr. Mark Nelson, commen","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","LU0158827948.USD","LU0006306889.USD","LU1023059063.AUD","LU1506573853.SGD","LU0314106906.USD","LU0976567544.SGD","LU2211815571.USD","IE00B19Z3B42.SGD","LU0456855351.SGD","LU2089283258.USD","LU2111349929.HKD","BK4568","BK4198","LU1057294990.SGD","IE00B3PB1722.GBP","SG9999003800.SGD","LU1989764664.SGD","BK7067","IE00B19Z3581.USD","LU2112291526.USD","LU2720916845.USD","LU0122379950.USD","LU0868494617.USD","LU0306806265.USD","LU1061106388.HKD","LU0320765489.SGD","LU2271345857.HKD","BK4082","BK4592","LU1983299246.USD","BK4550","GB00BDT5M118.USD","SG9999002224.SGD","IE00BBT3K403.USD","LU1992135399.USD","LU2272731600.USD","TLX","LU0265550946.USD","LU1894683348.USD","LU1291159041.SGD","LU2468319806.SGD","BK4599","LU0070302665.USD","LU0240877869.USD","LU0496365809.HKD","SG9999001176.SGD","LU1244550221.USD","BK4526","LU0106261372.USD","LU2272731782.SGD","IE00BQXX3F31.USD","LU1989771016.USD","LU2023251221.USD","BK4588","LU0289739699.SGD","LU1244550577.SGD","LU1992135472.HKD","LU0208291251.USD","IE00BQXX3C00.GBP","IE00BQXX3D17.EUR","IE00BVYPNW00.USD","LU0225284248.USD","LU1066053197.SGD","BK4109","LU1883839398.USD","LU0306807586.USD","BK4534","BK4585","LU2764263203.CNY","SG9999011175.SGD","IE000M9KFDE8.USD","LU1571399168.USD","LU0225771236.USD","SG9999001176.USD","IE00BGHQF631.EUR","LU2089284900.SGD","LU0211326755.USD","LU1989764748.USD","BK4543","LU0162691827.USD","LU0058720904.USD","LU0321505439.SGD","LU2089984988.USD","LU1116320901.HKD","LU0321505868.SGD","IE00BDGV0183.EUR","IE00BLSP4452.SGD","BK4139","LU0211326839.USD","IE00BFXG1179.USD","LU0205193047.USD","BK4141","SGXZ57979304.SGD","BK4533","IE00B42XCP33.USD","IE0002270589.USD","SG9999013999.USD","LU0170899867.USD","LU1066051498.USD","LU0240878834.USD","LU0205194284.USD","LU0265550359.USD","LU1894683264.USD","LU0211331839.USD","LU0432979614.USD","LU1244550494.USD","IE00BLSP4239.USD","LU0234572021.USD","LU0158827781.USD","LU2764262908.HKD","IE00B3T34201.USD","IE00BVYPNV92.GBP","SG9999002232.USD","BK4566","LU0985481810.HKD","BK4581","LU1116320737.USD","LU2764263039.SGD","LU2028103732.USD","LU0072461881.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626908978","title":"Telix appoints Maria Rivas, Bill Jellison as non-executive directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2626908978","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626908978?lang=en_us&edition=fundamental","pubTime":"2026-04-09 06:33","pubTimestamp":1775687638,"startTime":"0","endTime":"0","summary":"Telix expanded board with appointment of Maria Rivas and William “Bill” Jellison as non-executive directors, effective May 11, 2026.Rivas previously served as chief medical officer at Pfizer, with more than 25 years’ experience in late-stage clinical development and commercialization.Jellison previously served as CFO of Stryker, with more than 30 years’ experience in corporate finance and audit committee leadership.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Telix Pharmaceuticals Ltd. published the original content used to generate this news brief on April 09, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260408:nNDL2T8Kpb:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0306807586.USD","LU0456855351.SGD","BK4568","LU0225284248.USD","LU1066051498.USD","LU0058720904.USD","SG9999011175.SGD","LU0289739699.SGD","LU0868494617.USD","SG9999013999.USD","IE00B19Z3581.USD","IE00BBT3K403.USD","LU0170899867.USD","BK4588","SG9999003800.SGD","LU0122379950.USD","LU0985481810.HKD","LU1066053197.SGD","LU0306806265.USD","BK4007","BK4592","IE00BLSP4452.SGD","BK7067","SG9999002232.USD","LU1057294990.SGD","BK4585","LU0321505439.SGD","LU1894683348.USD","TLX","LU0234572021.USD","BK4533","LU1894683264.USD","BK4599","LU0321505868.SGD","SG9999001176.SGD","LU1023059063.AUD","LU1883839398.USD","IE0002270589.USD","IE00B19Z3B42.SGD","IE000M9KFDE8.USD","SG9999002224.SGD","BK4581","BK4534","SG9999001176.USD","BK4550","LU0225771236.USD","SGXZ57979304.SGD","IE00BLSP4239.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625691076","title":"Jarden Adjusts Telix Pharmaceuticals's Price Target to AU$21.80 from AU$21, Keeps at Buy","url":"https://stock-news.laohu8.com/highlight/detail?id=2625691076","media":"MT Newswires Live","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625691076?lang=en_us&edition=fundamental","pubTime":"2026-04-08 18:35","pubTimestamp":1775644502,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals (ASX:TLX) has an average rating of buy and mean price target of AU$24.76, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research fro","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["TLX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625962110","title":"Morgan Stanley Sticks to Its Buy Rating for Telix Pharmaceuticals (TLPPF)","url":"https://stock-news.laohu8.com/highlight/detail?id=2625962110","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625962110?lang=en_us&edition=fundamental","pubTime":"2026-04-08 07:36","pubTimestamp":1775604978,"startTime":"0","endTime":"0","summary":"In a report released today, David Bailey from Morgan Stanley maintained a Buy rating on Telix Pharmaceuticals, with a price target of A$24.60. Bail...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/morgan-stanley-sticks-to-its-buy-rating-for-telix-pharmaceuticals-tlppf-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/morgan-stanley-sticks-to-its-buy-rating-for-telix-pharmaceuticals-tlppf-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TLPPF","TLX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625629059","title":"Telix Pharmaceuticals (TLPPF) Gets a Buy from Canaccord Genuity","url":"https://stock-news.laohu8.com/highlight/detail?id=2625629059","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625629059?lang=en_us&edition=fundamental","pubTime":"2026-04-08 07:35","pubTimestamp":1775604946,"startTime":"0","endTime":"0","summary":"Canaccord Genuity analyst Shane Storey maintained a Buy rating on Telix Pharmaceuticals today and set a price target of A$28.50. According to TipRa...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/telix-pharmaceuticals-tlppf-gets-a-buy-from-canaccord-genuity-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/telix-pharmaceuticals-tlppf-gets-a-buy-from-canaccord-genuity-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TLPPF","TLX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625964685","title":"Telix Pharmaceuticals US PSMA PET Sales Gain Traction, Seen to Grow Market Share, Says Jefferies","url":"https://stock-news.laohu8.com/highlight/detail?id=2625964685","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625964685?lang=en_us&edition=fundamental","pubTime":"2026-04-08 06:44","pubTimestamp":1775601847,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals  reported strong US PSMA PET diagnostic sales in the first quarter, with a 5% rise, as focus shifts to regulatory updates for its investigational imaging agents Pixclara and Zircaix, Jefferies said Tuesday in a note.Jefferies expects the company to grow its PSMA PET diagnostic market share over the medium term, driven by approval of Gozellix product, which is projected to expand its addressable US PET scanners by 15%.The brokerage boosted its fiscal 2026 net profit after tax estimate to $3.3 million from $2 million, also updating its forecast for US and EU PSMA PET diagnostic sales, including US volumes of around 134,200 doses, up from 133,000 doses expected before.The company maintained its fiscal 2026 revenue guidance of $950 million to $970 million, compared with Jefferies' forecast of $965 million.Jefferies kept its buy rating and raised its price target to AU$24.30 from AU$23.40.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["TLX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625950201","title":"Why Is Telix Pharma Stock Soaring Tuesday?","url":"https://stock-news.laohu8.com/highlight/detail?id=2625950201","media":"Benzinga Earnings","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625950201?lang=en_us&edition=fundamental","pubTime":"2026-04-08 01:56","pubTimestamp":1775584600,"startTime":"0","endTime":"0","summary":"Telix Pharma stock climbs on strong Q1 growth and Phase 3 study success. Analysts maintain Buy ratings with price targets up to $22.00.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/markets/earnings/26/04/51688276/why-is-telix-pharma-stock-soaring-tuesday","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TLX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625953447","title":"Exchange-Traded Funds, Equity Futures Lower Pre-Bell Tuesday Ahead of Trump's Hormuz Reopening Deadline","url":"https://stock-news.laohu8.com/highlight/detail?id=2625953447","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625953447?lang=en_us&edition=fundamental","pubTime":"2026-04-07 21:01","pubTimestamp":1775566895,"startTime":"0","endTime":"0","summary":"The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was down 0.6% and the actively traded Invesco QQQ Trust (QQQ) was 0.7% lower in Tuesday's premarket activity, ahead of US President D","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["FAS","RDW","USO","IYJ","XLI","NMR","IPK","SOXX","XLY","BITO","VDC","XLP","IVV","XRT","IYE","IGM","SPY.AU","UNG","XLF","EXI","EETH","VHT","SPY","GLD","EQR","IYK","SLV","BETH","VIS","XLK","FAZ","TSLA","INFY","XLV","XLE","EEM",".DJI","PMR","IYH","IBB","IYW","MNR","TLX","RTH","FDN","VHT.AU","TLX.AU","RTH.AU","QQQ","XSD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625266932","title":"Telix Pharmaceuticals Price Target Maintained With a $20.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2625266932","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625266932?lang=en_us&edition=fundamental","pubTime":"2026-04-07 19:15","pubTimestamp":1775560500,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/TLX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 07, 2026 07:15 ET (11:15 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TLX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625985536","title":"Telix Pharmaceuticals Q1 Revenue Rises 24%; Shares Gain 6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2625985536","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625985536?lang=en_us&edition=fundamental","pubTime":"2026-04-07 09:57","pubTimestamp":1775527077,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals (ASX:TLX) reported first-quarter revenue of $230 million, up 24% from a year earlier, according to a Tuesday filing with the Australian bourse.First-quarter revenue for the compa","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["TLX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625830539","title":"Analysts Have Conflicting Sentiments on These Healthcare Companies: CSL (OtherCMXHF) and Telix Pharmaceuticals (OtherTLPPF)","url":"https://stock-news.laohu8.com/highlight/detail?id=2625830539","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625830539?lang=en_us&edition=fundamental","pubTime":"2026-04-07 09:40","pubTimestamp":1775526003,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on CSL (CMXHF) and Telix Pharmaceuticals (TLPPF). CSL (CMXHF) Macqua...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-csl-othercmxhf-and-telix-pharmaceuticals-othertlppf-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-csl-othercmxhf-and-telix-pharmaceuticals-othertlppf-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TLPPF","TLX","XLV","LU1169590202.USD","BK4585","XBI","BK4581","HCSG","BK4137","SG9999004303.SGD","LU0029874061.USD","LU0728928796.USD","CMXHF","CSL","SGXZ23171101.USD","LABU","BK4086","BK4139","LU1169589451.USD","BK4588","LU0128526141.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625233628","title":"Will Telix (ASX:TLX) Board Refresh Subtly Recast Its Governance And Growth Balancing Act?","url":"https://stock-news.laohu8.com/highlight/detail?id=2625233628","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625233628?lang=en_us&edition=fundamental","pubTime":"2026-04-06 04:12","pubTimestamp":1775419922,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals recently announced that David Gill will join its Board as a Non-Executive Director on 11 May 2026, with plans for him to succeed Dr. Mark Nelson as Chair while Nelson remains a Non-Executive Director.\nThe appointment brings a veteran life sciences executive with extensive radiopharmaceutical, capital markets and governance experience onto Telix’s Board, potentially reshaping how the company balances growth ambitions with oversight as a dual-listed business.\nWe’ll now...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-tlx/telix-pharmaceuticals-shares/news/will-telix-asxtlx-board-refresh-subtly-recast-its-governance","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-tlx/telix-pharmaceuticals-shares/news/will-telix-asxtlx-board-refresh-subtly-recast-its-governance","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["TLX","BK7067","TLX.AU","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624652093","title":"Citi Group Entities Exit Substantial Holder Status in Telix Pharmaceuticals","url":"https://stock-news.laohu8.com/highlight/detail?id=2624652093","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624652093?lang=en_us&edition=fundamental","pubTime":"2026-04-02 13:39","pubTimestamp":1775108345,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals ( ($AU:TLX) ) has shared an announcement. Citigroup Global Markets Australia and related Citi group entities have notified Te...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/citi-group-entities-exit-substantial-holder-status-in-telix-pharmaceuticals?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/citi-group-entities-exit-substantial-holder-status-in-telix-pharmaceuticals?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0052756011.USD","TLX","LU0310800965.SGD","LU2417539215.USD","LU2360032135.SGD","BK4585","LU1162221912.USD","LU0098860793.USD","IE00BSNM7G36.USD","LU1267930227.SGD","LU0320765646.SGD","LU0170899867.USD","LU0130517989.USD","BK4566","LU0477156953.USD","LU2456880835.USD","BK4534","LU1506573853.SGD","LU0314106906.USD","BK4207","BK4559","LU1668664300.SGD","LU0072461881.USD","LU2125154935.USD","LU1791807156.HKD","LU2462157665.USD","LU0106831901.USD","LU1244550221.USD","BK4504","LU1244550494.USD","LU0648001328.SGD","LU0980610538.SGD","LU1244550577.SGD","LU2236285917.USD","LU0130102774.USD","LU1366192091.USD","LU0128525689.USD","BK4139","BK4588","LU2125154778.USD","LU0162691827.USD","LU1201861249.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624547779","title":"Telix Appoints David Gill as Non-Executive Director","url":"https://stock-news.laohu8.com/highlight/detail?id=2624547779","media":"prnewswire","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624547779?lang=en_us&edition=fundamental","pubTime":"2026-04-02 06:59","pubTimestamp":1775084340,"startTime":"0","endTime":"0","summary":"Mr. Gill brings deep expertise in capital markets, scaling businesses, governance and corporate turn-around strategy and has served as Chief Financial Officer or President of multiple publicly traded companies, including EndoChoiceHoldings, Inc. , INC Research , and CTI Molecular Imaging . He holds a B.S. in Accounting from Wake Forest University and an MBA from Emory University.Telix Interim Chair, Mark Nelson, commented, \"We are pleased to welcome David to the Board, where his strong financial expertise and deep knowledge of U.S. capital markets will be highly valuable. We intend to further strengthen the Board through additional appointments aligned with our growth trajectory and governance needs as a dual-listed company.\". Telix Investor Relations Ms. Charlene JawAssociate Director Investor Relations[emailprotected]","market":"fut","thumbnail":"https://mma.prnewswire.com/media/1920208/Telix_Main_Logo_Logo.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/1920208/Telix_Main_Logo_Logo.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/telix-appoints-david-gill-as-non-executive-director-302732101.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QYLG","TLX.AU","BK4526","QQQY","ASX.AU","FTEC",".IXIC","IYW","INCR","BK4543","EOLS","BK4141","SQQQ","YMAB","BK4007","QID","QQQM","TQQQ","JEPQ","NDX","QQQE","GPIQ","TLX","BK7039","SBBP","SEC.AU","BK7067","NVIW.SI","QDTE","NQmain","BK4139","PSQ","ASX","QQQJ","MNQmain","QQQ","QLD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622809302","title":"Telix Pharmaceuticals (ASX:TLX) Is Up 7.1% After Resubmitting TLX101-Px NDA With FDA Fast Track Designation - Has The Bull Case Changed?","url":"https://stock-news.laohu8.com/highlight/detail?id=2622809302","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622809302?lang=en_us&edition=fundamental","pubTime":"2026-03-28 07:14","pubTimestamp":1774653245,"startTime":"0","endTime":"0","summary":"In March 2026, Telix Pharmaceuticals resubmitted its New Drug Application to the FDA for TLX101-Px (Pixclara, 18F-FET), an investigational PET imaging agent for distinguishing recurrent or progressive glioma from treatment effects in adult and pediatric patients, incorporating additional data and analysis requested after a prior Complete Response Letter.\nThe filing is significant because TLX101-Px holds both Orphan Drug and Fast Track designations and could become the first FDA-approved...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-tlx/telix-pharmaceuticals-shares/news/telix-pharmaceuticals-asxtlx-is-up-71-after-resubmitting-tlx","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-tlx/telix-pharmaceuticals-shares/news/telix-pharmaceuticals-asxtlx-is-up-71-after-resubmitting-tlx","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4585","TLX","LABU","BK4139","BK4588","BK7067","TLX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622895939","title":"ASX Growth Companies With Insider Ownership Up To 38%","url":"https://stock-news.laohu8.com/highlight/detail?id=2622895939","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622895939?lang=en_us&edition=fundamental","pubTime":"2026-03-27 03:08","pubTimestamp":1774552107,"startTime":"0","endTime":"0","summary":"As the Australian stock market experiences a modest rise amidst geopolitical uncertainties, investors are keeping a close watch on sectors poised for growth and resilience. In such an environment, companies with high insider ownership often attract attention due to the confidence they signal in their own potential, making them intriguing prospects for those seeking long-term growth opportunities.","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6033000-choice1-main-header/1585186824821","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6033000-choice1-main-header/1585186824821"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/healthcare/asx-reg/regis-healthcare-shares/news/asx-growth-companies-with-insider-ownership-up-to-38-2","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/healthcare/asx-reg/regis-healthcare-shares/news/asx-growth-companies-with-insider-ownership-up-to-38-2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["IQ","TLX.AU","BK4505","BK7007","BK4108","TLX","AEM.AU","BK7129","BK7110","CUV.AU","FEX.AU","AR1.AU","REG.AU","BK4139","CYC.AU","BK7016","BK4526","AV1.AU","BK4531","BK7095","EIQ.AU","MAU.AU","BK7508","BK4552","FRS.AU","TOR.AU","BK7113","BK7067","BK7017","BK7104"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621507720","title":"A Look At Telix Pharmaceuticals (ASX:TLX) Valuation After Key TLX101-Px And TLX591-Tx Trial Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2621507720","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621507720?lang=en_us&edition=fundamental","pubTime":"2026-03-23 12:27","pubTimestamp":1774240038,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals (ASX:TLX) has entered a busy regulatory phase, resubmitting its TLX101-Px New Drug Application for glioma imaging while also reporting that the lead-in stage of its TLX591-Tx Phase 3 prostate cancer trial met safety objectives.\nSee our latest analysis for Telix Pharmaceuticals.\nThese regulatory updates come after a strong short term run, with a 1 month share price return of 22.24% and a 7 day share price return of 12.93%. However, the 1 year total shareholder return is...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-tlx/telix-pharmaceuticals-shares/news/a-look-at-telix-pharmaceuticals-asxtlx-valuation-after-key-t","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-tlx/telix-pharmaceuticals-shares/news/a-look-at-telix-pharmaceuticals-asxtlx-valuation-after-key-t","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7067","TLX.AU","TLX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":10,"totalSize":199,"code":"91000000","status":"200"}]}}